Document is current
Any future updates will be listed below
-
Authors
Kristensen, Daniel Tuyet https://orcid.org/0000-0002-6753-7051
Brøndum, Rasmus Froberg https://orcid.org/0000-0001-5537-6767
Knudsen, Michael
Severinsen, Marianne Tang https://orcid.org/0000-0003-0996-1812
Grubach, Lykke
Andersen, Mette Klarskov
Cowland, Jack B.
Skov, Vibe https://orcid.org/0000-0003-0097-7826
Preiss, Birgitte
Ørnskov, Dorthe
Høgdall, Estrid
Poulsen, Tim Svenstrup
Kjeldsen, Eigil https://orcid.org/0000-0003-0897-7361
Bill, Marie
Ommen, Hans Beier https://orcid.org/0000-0001-7628-8694
Ørskov, Andreas Due
Schöllkopf, Claudia https://orcid.org/0000-0003-1465-506X
Hansen, Jakob Werner
Grønbæk, Kirsten https://orcid.org/0000-0002-1535-9601
Marcher, Claus Werenberg https://orcid.org/0000-0002-6595-2075
Hansen, Dennis Lund https://orcid.org/0000-0002-4478-1297
Larsen, Ole Halfdan
Bøgsted, Martin https://orcid.org/0000-0001-9192-1814
Roug, Anne Stidsholt
- License Information
-
More Information
Article History
Received: 17 February 2025
Revised: 15 June 2025
Accepted: 7 July 2025
First Online: 28 August 2025
COMPETING INTERESTS
: DTK: Consulting/advisory board: AbbVie, Astellas Pharma, Immedica pharma AB, Sevier; travel grants: Swedish Orphan Biovitrum; Research funding: unrestricted grant from Incyte Biosciences Nordic AB. LG: Speaker fee: GlaxoSmithKline. HBO: Research support: Jazz Pharmaceuticals. Consultancy: Daiichi Sankyo Nordics, AbbVie, Sanofi, Takeda. Travel grants: AbbVie. CS: Advisory board: Incyte Biosciences Distribution, Travel grants: Northon Healthcare Limited, Swedish Orphan Biovitrum, AbbVie. JWH: Consultancy, Otsuka Pharma, AbbVie. KG: Research Grant: Janssen, Consultancy: GSK, Otsuka Pharma. DLH: Consultancy/advisory board: Janssen and Takeda; Travel grants: EUSA Pharma, Alexion and Swedish Orphan Biovitrum. ASR: Consultancy/advisory board: Daiichi Sankyo Nordics, AbbVie, Immedica, Servier. Travel grants: Pfizer. All other authors declare no conflicts of interest.
: In accordance with Danish legislation, the study was registered in the internal project database in the North Denmark Region (ID-number: 2021-197), and informed consent was waived for this study in accordance with the Danish Health Care Act (ID-number: 2021-011009).
